Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Business and financial success concept. Modern collage with halftone hand holding a launching rocket, sales chart icons. Income growth. Successful startup. Increasing profits illustration

Startups

Versant Launches Fourth Obesity Startup Helicore to Improve Weight Loss Quality

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight loss.

January 28, 2025

2 min read

Tristan Manalac

Employer Resources

Report: 2025 Employment Outlook

In this Employment Outlook report, BioSpace explores current workforce sentiment, job activity trends and the prospective job and hiring outlook for 2025, particularly as it compares to the previous year.

January 28, 2025

1 min read

BioSpace Insights

Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc

Approvals

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners’ Datroway for a related type of breast cancer.

January 28, 2025

2 min read

Tristan Manalac

Signage at Pfizer's world headquarters in New York City

Business

Pfizer Gets Breather From Starboard’s Ongoing Assault

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by its current leadership. But Bloomberg reports it has missed the deadline for nominating a director to the pharma’s board.

January 28, 2025

2 min read

Tristan Manalac

Reaching an agreement. Businessmen shake hands and make a deal. vector

Depression

Neurocrine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

January 28, 2025

2 min read

Tristan Manalac

Balloons in the cloudy sky paper cutting art Sky background clouds, scene 3D illustration

Vaccines

Two Years Into Novavax Reset, CEO Jacobs Hunts for Silver Linings

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs says the company is at a pivot point.

January 28, 2025

6 min read

Annalee Armstrong

Pictured: Man prepares his GLP-1 injection

IPO

Metsera Seeks $289M Raise, $1.78B Valuation in IPO

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

January 27, 2025

1 min read

Dan Samorodnitsky

Pictured: Illustration of a human body with the liver highlighted

Drug Development

Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.

January 27, 2025

2 min read

Dan Samorodnitsky

Group Of Employees Being Fired By Their Company.

Layoffs

Allakos Will Axe 75% of Workforce, Drop Hives Candidate

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.

January 27, 2025

1 min read

Angela Gabriel

Visit website

Email Us

IN THE PRESS

Press Releases

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

June 2, 2025

4 min read

BioMidwest

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings